Pharmaceutical
Articles
Lilly announces replacements for two retiring executives
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
FDA approves Cialis for enlarged prostate
Cialis, Lilly’s blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men who suffer from both disorders can take one medication.
Lilly CEO says he’s not interested in Pfizer animal unit
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
Lilly’s Alimta get favorable opinion for new use in Europe
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
Debate rages over whether Lilly’s Byetta lifts cancer risk
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
Health regulatory leaders ready to flock to city
The top event for regulatory professionals in the health care industry is headed to Indianapolis next month. The annual conference of the Regulatory Affairs Professionals Society, or RAPS, is expected to draw thousands of members representing 120 companies and organizations.
FDA gets new report on Lilly diabetes drug
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
FDA deal with drugmakers raises user fees 6 percent
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
Endocyte completes secondary public offering
The West Lafayette-based biotech firm raised about $66.8 million by selling nearly 6.7 million shares of company stock, priced at $12.26 per share.
Lilly wins appeals court ruling in Strattera patent case
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.
Eli Lilly’s Elanco unit blossoming at just the right time
An investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass $3 billion by 2018.
Despite sales spike, Effient has middling prospects
Remember Effient? The blood thinner that was once Eli Lilly and Co.’s greatest post-Zyprexa hope and then, after a slow launch, was dismissed as an abject failure? Well, it’s turning out to defy both predictions.
UPDATE: Medco acquisition could lead to local consolidation
It’s not yet clear how Express Scripts Inc.’s $29.1 billion acquisition of rival Medco Health Solutions will affect the companies’ central Indiana operations—or their 800-plus employees at two facilities here.
Express Scripts to buy Medco for $29.1B in cash, stock
Express Scripts Inc. agreed to buy Medco Health Solutions Inc. for $29.1 billion to become the largest pharmacy-benefits manager in the United States. Both have central Indiana operations.
Lilly profit falls, but forecast rises after second quarter
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
Lilly: Alzheimer’s patients on failed drug didn’t improve
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
FDA says potential diabetes drug may cause cancer
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
Lechleiter: German drug pricing creates ‘uncertainty’ for Lilly
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.